Table 2.

Antibacterial activity of selected compounds against a panel of Gram‐positive bacteria.

Sp	Strain	Pt1	Pt2	Van[c]
Sa	ATCC 25923, MSSA	3.125[a]	1.56–3.125[a]	0.69
	ATCC 43300, MRSA	0.39[b]	0.39–0.78[b]	0.35–0.69
	NRS 17, GISA	0.78–0.56[b]	0.78–1.56[b]	5.52
	VRS 1, VRSA (VanA)	12.5[a]	6.25[a]	>44.2
Se	ATCC 14990, type strain	0.781[a]	1.56[a]	0.69–1.38
	NRS 60, VISE	3.125[a]	6.25[a]	2.76
Em	ATCC 35667, type strain	25[a]	25[a]	0.35
	ATCC 51559, MDR, VRE (VanA)	12.5[b]	12.5–25[b]	>44.2
	Clinical Isolate, VRE (VanA)	25–50[a]	25[a]	>44.2
Es	ATCC 29212, control strain	50–100[a]	25–50[a]	1.38–2.76
	Clinical Isolate, VRE (VanB)	25[a]	12.5–25[a]	>44.2
Bs	ATCC 6051, type strain	6.25[b]	3.125–6.25[b]	0.35

Antibacterial activity is displayed as MIC μg/mL. Sp – Species; Sa – Staphylococcus aureus; Se – Staphylococcus epidermidis; Em – Enterococcus faecium; Es – Enterococcus faecalis; Bs – Bacillus subtilis; MSSA – methicillin susceptible S. aureus; MRSA – methicillin resistant S. aureus; MDR – multidrug resistant; GISA – glycopeptide intermediate S. aureus; VRSA – vancomycin resistant S. aureus; VISE – vancomycin intermediate S. epidermidis; VRE – vancomycin resistant Enterococcus; VanA and VanB are vancomycin resistance genes. [a] MIC determined with n=4 [b] MIC determined with n=2. [c] Vancomycin stock solution was prepared at 2.56 μg/mL and highest tested concentration was 64 μg/mL (44.2 μM).